Professor Nicholas Reed has been a consultant in clinical oncology at the Beatson Oncology Centre (BOC), Glasgow, United Kingdom since September 1984. In 2012, hewas appointed as an Honorary Professor in Oncology at University of Glasgow. He was appointed Clinical Director in April 1996 completing his term of office in June 2003.
His main clinical interests lie in the thyroid and neuroendocrine cancers and gynaecological cancer. As a result of this he has also had a special interest in the management of rare cancers. He was a founding member and former secretary and later Chairman of the UKINETS (UK & Ireland Neuro-Endocrine Tumour Society), and more recently a member of the European NeuroEndocrine Tumour Society (ENETS) and sits on the Advisory Board. He currently is Chairman of the scientific abstract committee for the annual ENETs conference.
In the past five years, through UKINET and the NCRN Clinical Studies Groups, he has successfully been active in clinical trials in these areas, and he has been the principal investigator for a number of studies. In thyroid cancer he has also been active clinical research acting as principal investigator and chief UK investigator for a number of studies. He helped to found and foster SCONET bringing together Scottish experts in NET tumours.
He was Secretary and later Chairman of the EORTC GCG (Gynaecological Cancer Group) between 2003 and 2009. He has been a long-term member of British Gynaecological Cancer Society and has spent two terms as council member. He has also been a member of ESGO (European Society of Gynaecological Oncology) and joined the council becoming a Vice President.
Prof. Reed has been an active member of the Scottish Gynaecological Cancer Trial Group, the NCRN Gynaecological Cancer Clinical Studies Group, including a term as Chair of the cervix cancer sub-committee. He was a founder member of the Gynaecological Cancer InterGroup (GCIG) and was facilitator of the Rare Tumour Sub-Group from 2000-2009.
He is now working part-time but continues with the Thyroid and NET cancer practice and has recently established a new clinic for rare gynaecological cancers in West of Scotland.